Abstract
The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used.
Copyright © 2016 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Neutralizing / immunology
-
Antibodies, Neutralizing / therapeutic use*
-
Antibodies, Viral / immunology
-
Antibodies, Viral / therapeutic use*
-
Ebolavirus / immunology*
-
Epitopes / immunology
-
Hemorrhagic Fever, Ebola / therapy*
-
Hemorrhagic Fever, Ebola / virology
-
Humans
-
Immunotherapy / methods*
-
Mice
-
Viral Envelope Proteins / immunology*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Epitopes
-
Viral Envelope Proteins
-
envelope glycoprotein, Ebola virus